A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer

NCT02443467 · clinicaltrials.gov ↗

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer, Early Breast Cancer

Interventions

OTHER: No intervention

Sponsor

Hoffmann-La Roche